The BCL-2 arbiters of apoptosis and their growing role as cancer targets, Cell Death Differ, vol.25, pp.27-36, 2018. ,
Structure of Bcl-x L-Bak peptide complex: recognition between regulators of apoptosis, Science, vol.14, pp.983-986, 1997. ,
Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX, Cell Res, vol.21, pp.627-641, 2011. ,
Rationale for Bcl-x L /Bad peptide complex formation from structure, mutagenesis, and Biophysical studies, Protein Sci, vol.9, pp.2528-2534, 2000. ,
Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands, J. Biol. Chem, vol.284, pp.30508-30517, 2009. ,
Apoptotic regulation by MCL-1 through heterodimerization, J. Biol. Chem, vol.285, 2010. ,
Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1, J. Mol. Biol, vol.380, pp.958-971, 2008. ,
Structural insights into the degradation of Mcl-1 induced by BH3 domains, Proc. Natl. Acad. Sci. U.S.A, vol.104, pp.6217-6222, 2007. ,
Bcl2 family proteins in carcinogenesis and the treatment of cancer, Cell Death Dis, vol.14, pp.584-596, 2009. ,
Bcl-x L and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis, Int. J. Canc, vol.126, pp.885-895, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01650312
Absence of Bcl-x L down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells, Gynecol. Oncol, vol.105, pp.31-44, 2007. ,
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized, Cancer Cell, vol.10, pp.389-399, 2006. ,
Mcl-1 down-regulation potentiates ABT-737 Lethality by cooperatively inducing Bak activation and Bax translocation, Cancer Res, vol.67, pp.782-791, 2007. ,
Targeting the BH3 domain of Bcl-2 family proteins. A brief history from natural products to foldamers as promising cancer therapeutic avenues, Curr. Med. Chem, vol.20, pp.2964-2978, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00918387
Why do BCL-2 inhibitors work and where should we use them in the clinic?, Cell Death Differ, pp.1-9, 2017. ,
An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, vol.435, pp.677-681, 2005. ,
, ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor, vol.68, pp.3421-3428, 2008.
Activity of the Bcl-2 family InhibitorABT-263 in a panel of small cell lung cancer xenograft models, Clin. Canc. Res, vol.14, pp.3268-3277, 2008. ,
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity, Lancet Oncol, vol.11, pp.1149-1159, 2010. ,
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease, J. Clin. Oncol, vol.30, pp.488-496, 2012. ,
Phase I study of navitoclax (ABT263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors, J. Clin. Oncol, vol.29, pp.909-916, 2011. ,
Programmed anuclear cell death delimits platelet Life span, Cell, vol.128, pp.1173-1186, 2007. ,
, Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia, pp.1-12, 2015.
ABT-199, a potent and selective BCL-2 inhibitor, Nature Medecine, vol.19, pp.202-210, 2013. ,
BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells, Cancer Res, vol.75, pp.1366-1375, 2015. ,
Mcl-1 is a potential therapeutic target in multiple types of cancer, Cell. Mol. Life Sci, vol.66, pp.1326-1336, 2009. ,
, The landscape of somatic copy-number alteration across human cancers, vol.463, pp.899-905, 2010.
PI3K/ mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-x L-targeting strategies, Cancer Lett, vol.348, pp.38-49, 2014. ,
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1, Clin. Canc. Res, vol.8, pp.3527-3538, 2002. ,
Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-x L strategies through Mcl-1 down-regulation, Apoptosis, vol.20, pp.535-550, 2015. ,
The mTORC1/2 inhibitor AZD8055 strengthens the efficiency of the MEK inhibitor trametinib to reduce the Mcl-1/[Bim and Puma] ratio and to sensitize ovarian carcinoma cells to ABT-737, Mol. Canc. Therapeut, vol.16, pp.102-115, 2017. ,
The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer, Nat. Chem. Biol, vol.6, pp.595-601, 2010. ,
Rational design of proteolytically stable, cell-permeable peptide-based selective Mcl-1 inhibitors, J. Am. Chem. Soc, vol.134, pp.14734-14737, 2012. ,
, The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models, pp.1-5, 2016.
First evidence that oligopyridines, ahelix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-x Ltargeting strategies, J. Med. Chem, vol.58, pp.1644-1668, 2015. ,
A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival, Chem. Biol, vol.19, pp.1175-1186, 2012. ,
The. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax), Cell Death Dis, vol.6, pp.1-11, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01638832
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors, Nat. Rev. Drug Discov, vol.16, pp.273-284, 2017. ,
Small molecule Mcl-1 inhibitors for the treatment of cancer, Pharmacol. Ther, vol.145, pp.76-84, 2015. ,
Small-molecule and peptide inhibitors of the prosurvival protein Mcl-1, ChemMedChem, vol.11, pp.802-813, 2016. ,
Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein, Bioorg. Med. Chem. Lett, vol.24, pp.1484-1488, 2014. ,
Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker, Bioorg. Med. Chem. Lett, vol.21, pp.6642-6649, 2013. ,
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity, J. Med. Chem, vol.58, pp.2180-2194, 2015. ,
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer, Sci. Transl. Med, vol.9, p.7049, 2017. ,
Structural characterizations of oligopyridyl foldamers, alpha-helix mimetics, J. Chem. Inf. Model, vol.52, pp.429-439, 2012. ,
Conformation control of abiotic alpha-helical foldamers, J. Chem. Inf. Model, vol.53, pp.2671-2680, 2013. ,
MalzertFr eon, Comparison of 2 strategies to enhance pyridoclax solubility: nanoemulsion delivery system versus salt synthesis, Eur. J. Pharmaceut. Sci, vol.97, pp.218-226, 2017. ,
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x L , but not Bcl-2, until displaced by BH3-only proteins titre Genes, Devenir, vol.19, pp.1294-1305, 2005. ,
Toward understanding Mcl-1 promiscuous and specific binding mode, J. Chem. Inf. Model, vol.57, pp.2885-2895, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02043710
Structural biology of the Bcl-2 family of proteins, Biochim. Biophys. Acta, vol.1644, pp.83-94, 2004. ,
Hydrophile scanning as a complement to alanine scanning for exploring and manipulating proteinprotein recognition: application to the Bim BH3 domain, Protein Sci, vol.17, pp.1232-1240, 2008. ,
Structure property relationships of carboxylic acid isosteres, J. Med. Chem, vol.59, pp.3183-3203, 2016. ,
Recent developments in the chemistry and in the biological applications of amidoximes, Curr. Pharmaceut. Des, vol.14, pp.1001-1047, 2008. ,
An efficient two-step total synthesis of the quaterpyridine nemertelline, J. Org. Chem, vol.68, pp.10178-10180, 2003. ,
Synthesis of dihalo bi-and terpyridines by regioselective Suzuki-Miyaura crosscoupling reactions, Tetrahedron, vol.65, pp.5413-5417, 2009. ,
, Terpyridines using iterative cross-coupling reactions, vol.16, pp.2804-2810, 2010.
URL : https://hal.archives-ouvertes.fr/hal-02045907
Using halo (het) arylboronic species to achieve synthesis of foldamers as protein-protein interaction disruptors, Pure Appl. Chem, vol.84, pp.2467-2478, 2012. ,
A general synthesis of halo-oligopyridines. The Garlanding concept, Tetrahedron, vol.65, pp.607-612, 2009. ,
Selective palladium-catalyzed suzukiemiyaura reactions of polyhalogenated heteroarenes, Adv. Synth. Catal, vol.354, pp.1181-1255, 2012. ,
, Tetrahedron, vol.66, pp.668-675, 2010.
, Focus on microwaves assisted halogen-halogen reaction conditions on 2halopyridines, vol.1, pp.75-80, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00997593
Efficacy and biological correlates of response in a phase II study of Venetoclax monotherapy in patients with acute myelogenous leukemia, Cancer Discov, vol.6, pp.1106-1117, 2016. ,
Identification of predictive factors of response to the BH3mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma, Int. J. Canc, vol.136, pp.340-350, 2015. ,
, Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia, vol.10, pp.375-388, 2006.
Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia, Blood, vol.126, pp.363-372, 2015. ,
Inhibition of Mcl-1 enhances cell death induced by the Bcl-2selective inhibitor ABT-199 in acute myeloid leukemia cells, Signal Transduct. Targeted Ther, vol.2, p.17012, 2017. ,
The discovery and preclinical characterization of AMG 176: a first-in-class Mcl-1 inhibitor in clinical development for multiple myeloma, Proceedings of the American Association for Cancer Research Annual Meeting, vol.77, 2017. ,
Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer models, Proceedings of the American Association for Cancer Research Annual Meeting, vol.77, 2017. ,
Rational design of therapeutics targeting the BCL2 family: are some cancer cells primed for death but waiting for a final push, Adv. Exp. Med. Biol, vol.615, pp.159-175, 2008. ,
Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation, J. Mol. Biol, vol.245, pp.43-53, 1995. ,
Development and validation of a genetic algorithm for flexible docking, J. Mol. Biol, vol.267, pp.727-748, 1997. ,
Discovery of 2-Indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods, J. Med. Chem, vol.59, pp.2054-2066, 2016. ,
, Discovery Studio Modeling Environment, 2016.
Scalable molecular dynamics with NAMD, J. Comput. Chem, vol.26, pp.1781-1802, 2005. ,
Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the Backbone f, j and side-chain c1 and c2 dihedral angles, J. Chem. Theor. Comput, vol.8, pp.3257-3273, 2012. ,
CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force field, J. Comput. Chem, vol.31, pp.671-690, 2010. ,
Extension of the CHARMM general force field to sulfonyl-containing compounds and its utility in biomolecular simulations, J. Comput. Chem, vol.33, pp.2451-2468, 2012. ,
Comparison of simple potential functions for simulating liquid water, J. Chem. Phys, vol.79, pp.926-935, 1983. ,
CHARMM-GUI: a web-based graphical user interface for CHARMM, J. Comput. Chem, vol.29, pp.1859-1865, 2008. ,
Particle mesh Ewald: an N$log(N) method for Ewald sums in large systems, J. Chem. Phys, vol.98, pp.10089-10092, 1993. ,
Numerical integration of the cartesian equations of motion of a system with constraints: moleculardynamics of n-alkanes, J. Comput. Phys, vol.23, pp.327-334, 1977. ,
CHARMM: the biomolecular simulation program, J. Comput. Chem, vol.30, pp.1545-1614, 2009. ,
Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control, Int. J. Canc, vol.78, pp.454-463, 1998. ,